Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest (see below for definitions).

Commercial Interest

The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships

Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Speakers, Moderators, Chairs

CHAIR:
Judy C. Boughey, MBBCh, FACS – Nothing to disclose
Professor of Surgery, Mayo Clinic, Rochester, MN

CO-CHAIR:
Kamal M. Itani, MD, FACS - Eupraxia pharmaceuticals: Consulting Fee: Consultant, Pfizer: Institutional grant: PI
Chief of Surgery VABHCS, Professor of Surgery, Boston University, VA Boston Healthcare System, Surgical Service, West Roxbury, MA

Peter R. Nelson, MD, MS, FACS – Nothing to disclose
Professor of Surgery, Vascular Surgery, University of Oklahoma, Tulsa, OK 

Matthew H.G. Katz, MD, FACS – Nothing to disclose
Associate Professor, MD Anderson Cancer Center, Department of Surgical Oncology, Division of Surgery, Houston, TX 

Karla V. Ballman, PhD - Eli Lilly: Honorarium: Expert witness for Cialis and Melanoma
Johnson and Johnson: Honorarium: Expert witness for talcum power and ovarian cancer
Johnson and Johnson: Honorarium: Expert witness in abiraterone patent infringement case
Takeda: Honorarium: Data Safety and Monitoring Committee (trial using brigatinib)
Professor and Chief of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY 

James W. Fleshman, MD, FACS – Nothing to disclose
Chief of Surgery, Baylor University Medical, Department of Surgery, Dallas, TX 

Eric L. Lazar, MD, MS, FACS – Nothing to disclose
Associate Professor of Surgery, Rutgers University New Jersey Medical School, Mendham, NJ 

George A. Sarosi, MD, FACS – Nothing to disclose
Professor, NF/SG VA Medical Center, Gainesville, FL 

Anna Weiss, MD – Nothing to disclose
Assistant Professor of Surgery, Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA 

Edward H. Livingston, MD, FACS – Nothing to disclose
Chief Editor for JAMA, Adjunct Professor of Surgery, University of Texas Southwestern School of Medicine, Northwestern University, Chicago, IL

Program Committee and Disclosures

Amanda Francescatti, MS – Nothing to disclose
Linda Zheng – Nothing to disclose
 

Planning Committee

CHAIR:
Judy C. Boughey, MBBCh, FACS – Nothing to disclose
Professor of Surgery, Mayo Clinic, Rochester, MN

CO-CHAIR:
Kamal M. Itani, MD, FACS - Eupraxia pharmaceuticals: Consulting Fee: Consultant, Pfizer: Institutional grant: PI
Chief of Surgery VABHCS, Professor of Surgery, Boston University, VA Boston Healthcare System, Surgical Service, West Roxbury, MA

Peter R. Nelson, MD, MS, FACS – Nothing to disclose
Professor of Surgery, Vascular Surgery, University of Oklahoma, Tulsa, OK 

Matthew H.G. Katz, MD, FACS – Nothing to disclose
Associate Professor, MD Anderson Cancer Center, Department of Surgical Oncology, Division of Surgery, Houston, TX 

Karla V. Ballman, PhD - Eli Lilly: Honorarium: Expert witness for Cialis and Melanoma
Johnson and Johnson: Honorarium: Expert witness for talcum power and ovarian cancer
Johnson and Johnson: Honorarium: Expert witness in abiraterone patent infringement case
Takeda: Honorarium: Data Safety and Monitoring Committee (trial using brigatinib)
Professor and Chief of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY 

James W. Fleshman, MD, FACS – Nothing to disclose
Chief of Surgery, Baylor University Medical, Department of Surgery, Dallas, TX 

Eric L. Lazar, MD, MS, FACS – Nothing to disclose
Associate Professor of Surgery, Rutgers University New Jersey Medical School, Mendham, NJ 

George A. Sarosi, MD, FACS – Nothing to disclose
Professor, NF/SG VA Medical Center, Gainesville, FL 

Anna Weiss, MD – Nothing to disclose
Assistant Professor of Surgery, Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA 

Edward H. Livingston, MD, FACS – Nothing to disclose
Chief Editor for JAMA, Adjunct Professor of Surgery, University of Texas Southwestern School of Medicine, Northwestern University, Chicago, IL

Amanda Francescatti, MS – Nothing to disclose
Linda Zheng – Nothing to disclose